## HETEROCYCLES, Vol. 60, No. 11, 2003, pp. 2417 - 2424 Received, 23rd June, 2003, Accepted, 10th September, 2003, Published online, 16th September, 2003

## SYNTHESIS OF FURAZANE CONJUGATED NEW HETEROCYCLES

Renaud Beaudegnies\* and Sebastian Wendeborn

Syngenta Crop Protection AG, Optimization Chemistry CH-4002 Basel, Switzerland E-mail: renaud.beaudegnies@syngenta.com

**Abstract**- An improved route for the synthesis of 3-(4-aminofurazane-3-yl)-1,2,4oxadiazole heterocycles using micro-wave irradiation is reported. The preparation of novel 4-(thiazol-4-yl)furazan-3-ylamine, 4-(pyrimidin-4-yl)furazan-3-ylamine and, 4-(pyrazolidin-3-yl)furazan-3-ylamine heterocycles are described.

Furazanes (1,2,5-oxadiazoles) have been reported to exhibit a wide spectrum of biological properties.<sup>1</sup> In particular, agrochemical applications of furazanes and their derivatives as herbicides, plant-growth regulators and pesticides have been described.<sup>2</sup> Our biological screening revealed that 3-(4-aminofurazan-3-yl)-4H-[1,2,4]oxadiazol-5-one (5) exhibits herbicidal activity on broad leaf (*dicotyledones*) weeds. This prompted us to investigate the synthesis of novel 4-aminofurazane heterocycles.

In the first part of this communication we report the preparation of **5** as well as a new and efficient method for the high speed synthesis of [3-(4-aminofurazan-3-yl)-4H-[1,2,4] oxadiazol-5-yl]amine derivatives (**4**).

In the second part, we report the preparation of novel 4-aminofurazane rings conjugated to thiazole, pyrimidine and pyrazolidine heterocycles.


Few examples reported in literature describing synthesis of have been the the 3-(4-aminofurazan-3-yl)-[1,2,4] oxadiazole heterocycles.<sup>3</sup> 4-(5-Trichloromethyl[1,2,4] oxadiazol-3-yl)furazan-3-ylamine (3) appeared to be the intermediate of choice for the preparation of both 3-(4-aminofurazan-3-yl)-4*H*-[1,2,4]oxadiazol-5-one (5) and [3-(4-aminofurazan-3-yl)-4*H*new [1,2,4]oxadiazol-5-yl]amine derivatives (4a-p) (Scheme 1). Indeed, it has been reported that the trichloromethyl group at the C-5 position of a 1,2,4-oxadiazole ring can be readily substituted by nucleophiles such as guanidines to yield 5-amino-1,2,4-oxadiazole derivatives.<sup>4</sup>

The sequence followed for the preparation of the amide oxime (3) is similar to the one previously published by Andrianov *et al.*<sup>3d</sup> However, their one-pot procedure for the preparation of 3 directly from  $1^5$  could not be reproduced in our hands (lit.,<sup>3d</sup> 58%). Our new stepwise pathway involves intermediate (2) and provides 3 more efficiently from 1 (77% yield two steps). Treatment with *p*-toluidine was required for the selective removal of the trichloroacetyl group of the intermediate (2) which provides 3 in 81% yield. The ammonolysis of 3 in the presence of  $NH_4OH$  gave 5 (87% yield).

In order to access a number of structurally diverse analogs of **5**, a small library was prepared by treating **3** with a series of both primary and secondary amines. When the reaction was performed in EtOH/THF at 70°C (method A), the reaction was slow (2-3 days) and low yielding, but nonetheless provided a number of pure [3-(4-aminofurazan-3-yl)-4*H*-[1,2,4]oxadiazol-5-yl]amines after crystallisation.

The efficiency of the process could be drastically improved when **3** and 1.2 eq. of amine were adsorbed together on neutral alumina and irradiated in the microwave oven at 400 W (method B). Under these conditions, the reactions were much faster (< 20 min) and substantially cleaner.

The compounds prepared by these two methods are summarized in Table 1.




**Scheme 1.** a) NaNO<sub>2</sub> (2 eq.), HCl (2N), rt, 5 h; b) NH<sub>2</sub>OH.HCl (2.2 eq.), NaOH (pH=10), rt; c) reflux, 3 h; d) (CCl<sub>3</sub>CO)<sub>2</sub>O, 120°C, 5 h; e) *p*-toluidine (2 eq.), C<sub>2</sub>H<sub>5</sub>OH, 80°C, 19 h; f) (CCl<sub>3</sub>CO)<sub>2</sub>O, 60-80°C (lit.,<sup>2d</sup> 58%); g) **method A** : amine (3-5 eq.), C<sub>2</sub>H<sub>5</sub>OH, 70°C, 2-3 d.; h) **method B** : amine (1.2 eq.) on neutral alumina, microwave (400W), 2x10 min.; i) 25% NH<sub>4</sub>OH.

 Table 1. Transformation of 3 into 4


entry	amine	method	product	yield	entry	amine	method	product	yield
1	NH <sub>2</sub>	A	4a	<5%	12	H <sub>2</sub> N F	В	4f	90%
2	NH <sub>2</sub>	В	<b>4</b> a	quant.	13	CH <sub>3</sub> O OCH <sub>3</sub>	Α	4g	44%
3	H <sub>2</sub> N	A	4b	15%	14	H <sub>2</sub> N CF <sub>3</sub>	А	4h	81%
4	H <sub>2</sub> N	В	4b	quant.	15	H <sub>2</sub> N	А	<b>4</b> i	90%
5	H <sub>2</sub> N	А	4c	65%	16	H <sub>2</sub> N F	А	4j	88%
6	H <sub>2</sub> N	В	4c	95%	17	F NH <sub>2</sub>	A	4k	79%
7	H <sub>2</sub> N OCH <sub>3</sub>	A	4d	30%	18	NH <sub>2</sub>	А	41	43%
8	H <sub>2</sub> N OCH <sub>3</sub>	В	4d	88%	19	H <sub>2</sub> N <sub>0</sub>	А	4m	57%
9	H <sub>2</sub> N CF <sub>3</sub>	А	4e	33%	20	NH <sub>2</sub>	А	4n	70%
10	H <sub>2</sub> N CF <sub>3</sub>	В	<b>4</b> e	86%	21	H <sub>2</sub> N OCH <sub>3</sub>	В	40	96%
11	H <sub>2</sub> N F	А	4f	39%	22	H,	А	4p	36%

We also report the preparation of novel 4-aminofurazanes bearing 5- or 6- membered ring heterocycles.<sup>6</sup> Their syntheses use 1-(4-aminofurazan-3-yl)ethanone  $(10)^{7,8}$  as a key intermediate (Schemes 3 and 4). It has been reported that such 3-acylated furazane rings can be prepared through the reduction of the corresponding carbonyl-substituted furoxans.<sup>7</sup> We report here a new synthesis of 10 as depicted in Scheme 2 in which the key step is the mild and regioselective cyclisation of **8** induced by the treatment with NaOAc in dioxane at 60°C, to give **9** in high yield.



Scheme 2. a) isopentyl nitrite,  $(C_2H_5)_2O$ , HCl; b) KCN (1.8 eq.),  $(C_2H_5)_2O$ , H<sub>2</sub>O, 45°C; c) H<sub>2</sub>NOH.HCl, NaOH, H<sub>2</sub>O, rt; d) Ac<sub>2</sub>O, O°C-rt; e) NaOAc (4 eq.), dioxane, 60°C; f) 20% HCl, H<sub>2</sub>O, reflux, steam distillation.

1-(4-Aminofurazan-3-yl)ethanone (10) was brominated according to reported conditions.<sup>8b</sup> Thiazole derivatives (12 and 13) were prepared in 26 to 99% yields through the Hantzsch reaction of bromide (11)<sup>8b</sup> and the corresponding thioamides or thioureas (Scheme 3 and Table 2).<sup>9</sup>



Scheme 3. a)  $Br_2$  (1.05 eq.), AcOH (100%), 55°C; b) method A: 1.1 eq. nucleophile, benzene, reflux, 2-3 h, Dean-Stark; c) method B: 1.1 eq. nucleophile, C<sub>2</sub>H<sub>5</sub>OH, reflux, 2-3 h.





Table 2. Synthesis of 4-(thiazol-4-yl)furazan-3-ylamine derivatives (12) and (13)

4-(Pyrimidin-4-yl)furazan-3-ylamine and 4-(pyrazolidin-3-yl)furazan-3-ylamine heterocycles (**18-23** and **24** to **31**) respectively are available in three steps from **10** *via* the reaction of **15** with ambident nucleophiles such as amidines, guanidines or hydrazines (Scheme 4 and Table 3).

As shown in the Scheme 4, triphenylphosphorane (14) did not react with aldehydes and only starting materials were recovered. In contrast, piperidine catalyzed aldol condensations between 10 and various aldehydes proceeded in satisfactory to excellent yields (Scheme 4).

The resulting  $\alpha$ , $\beta$ -unsaturated ketones (15, 16, and 17) were allowed to react with amidines and guanidines in the presence of oxygen to give 4-(pyrimidin-4-yl)furazan-3-ylamine derivatives (24 to 31) in low to moderate yields. Compounds (15 and 17) underwent reaction with hydrazine to give oxygen sensitive 4-(pyrazolidin-3-yl)furazan-3-ylamine heterocycles which were directly acylated with various acid chlorides in good yields, thus allowing the introduction of additional points of diversity.



**Scheme 4.** a)  $Br_2$  (1.05 eq.), AcOH (100%), 55°C; b)  $R^1$ CHO (2.0 eq.), piperidine (0.1 eq.),  $C_2H_5$ OH /THF: 5/1, 50°C; c) PPh<sub>3</sub> (1.0 eq.), toluene, 100°C; d) NaOH (2N), CH<sub>3</sub>OH, 0°C; e)  $R^1$ CHO (1.2 eq.), piperidine (0.1 eq.), 60°C; f) amidine or guanidine (1.1 eq.), *N*,*N*-dimethylacetamide, 60°C, O<sub>2</sub> (gas); g) PhNHNH<sub>2</sub> (2.0 eq.), THF/  $C_2H_5$ OH: 1/20, rt; h)  $H_2$ NNH<sub>2</sub>.H<sub>2</sub>O (10 eq.), THF, rt; i)  $R^3$ COCl (1.2 eq.), pyridine (3.0 eq.), CH<sub>2</sub>Cl<sub>2</sub>, rt.

Table 3. Synthesis of compounds (18 to 31)

entry	educt	R1	R2	product	yield	entry	educt	R1	R3	product	yield
1*	15	cyclopropyl	methyl	18	29%	8	15	cyclopropyl		25	92%
2	15	cyclopropyl	<i>p</i> -methoxyphenyl	19	14%	9	17	2-furyl		26	99%
3	15	cyclopropyl	phenyl	20	26%	10	25	cyclopropyl	methyl	27	74%
4	15	cyclopropyl	aniline	21	16%	11	26	2-furyl	2,4-dichlorophenyl	28	92%
5	15	cyclopropyl	benzylamine	22	25%	12	26	2-furyl	(4-chlorophenoxy)methyl	29	76%
6	16	<i>p</i> -methoxyphenyl	<i>m</i> -methylaniline	23	56%	13	26	2-furyl	2-furyl	30	73%
7	17	2-furyl		24	26%	14	26	2-furyl	cyclopropyl	31	79%

(\*) Performed in the presence of 1.1 eq. of DBU.

## CONCLUSION

We have developed a new and efficient method for the synthesis of [3-(4-aminofurazan-3-yl)-4*H*-[1,2,4]oxadiazol-5-yl]amine derivatives. We have also enlarged the scope of the 4-aminofurazane chemistry to novel 4-(thiazol-4-yl)furazan-3-ylamine, 4-(pyrimidin-4-yl)furazan-3-ylamine and, 4-(pyrazolidin-3-yl)furazan-3-ylamine heterocycles.

## REFERENCES

- 1. R.M. Paton, *Comprehensive Heterocyclic Chemistry II*, ed. by A.R. Katritsky, C.W. Rees, and E.F.V. Scriven, Pergamon, Oxford, 1996, **4**, 229 and references cited therein.
- (a) J.C. Bottaro, M.A. Petrie, P.E. Penwell, and D.C. Bomberger, *PCT Int. Appl.*, 2003, WO 0306371A1 (*Chem. Abstr.*, 2003, **138**, 126950); (b) H. Cerecetto, E. Dias, R. Di Maio, M.Gonzalez, S. Pacce, P. Saenz, G. Seoane, L. Suescun, A. Mombru, G. Fernandez, M. Lema, and J. Villalba, *J. Agric. Food Chem.*, 2000, **48**, 2995; (c) *Ger. Offen.*,1985, DE 3326509A1 (*Chem. Abstr.*, 1985, **102**, 220879h); (d) R.W.W. Baldwin, *U.S. Patent*, 1970, US 3501285 (*Chem. Abstr.*, 1970, **72**, 111477s); (e) *French Patent*, 1969, FR 1576140 (*Chem. Abstr.*, 1970, **72**, 110178h); (f) W.E. Buting and C. Ainsworth, *U.S. Patent*, 1966, US 3279988 (*Chem. Abstr.*, 1967, **66**, 28776u).
- (a) S.D. Shaposhnikov, N.V. Korobov, A.V. Sergievskii, S.V. Pirogov, S.F. Mel'nikova, and I.V. Tselinskii, *Russian J. Org. Chem.*, 2002, **38**, 1351; (b) S. Bailey, P.V. Fish, K. James, and G.A. Whitlock, *PCT Int. Appl.*, 2002, WO 0279200A1 (*Chem. Abstr.*, 2002, **137**, 294960); (c) V.N. Yarovenko, V.Z. Shirinyan, I.V. Zavarzin, and M.M. Krayushkin, *Izv. Akad. Nauk, Ser. Khim.* 1994, 118; (d) V.G. Andrianov, E.N. Rozhkov, and A.V. Eremeev, *Khim. Geterotsikl. Soedin.*, 1994, 534; (e) V.G. Andrianov, V.G. Semenikhina, and A.V. Eremeev, *Khim. Geterotsikl. Soedin.*, 1994, 539; f) O.A. Rakitin, V.A. Ogurtsov, E.A. Khaibullina, T.I. Godovikova, and L.I. Khmel'nitskii, *Khim. Geterotsikl. Soedin.*, 1993, 1283; (g) V.G. Andrianov, V.G. Semenikhina, and A.V. Eremeev, *K. Soedin.*, I.V. Zavarzin, and M.M Krayushkin, *Izv. Akad. Nauk, Ser. Khim.* 1991, 2166; i) V.N. Yarovenko, V.K.Taralashvili, I.V. Zavarzin, and M.M Krayushkin, *Tetrahedron*, 1990, **46**, 3941.
- 4. (a) I. Kumita, A. Niwa, C. Sano, and M. Takagi, *Jpn. Kokai Tokkyo Koho*, 1993, JP 05117255A2 (*Chem. Abstr.*, 1993, **119** : P271167h); (b) J.L. LaMattina and C.J. Mularski, *J. Org. Chem.*, 1984, **49**, 4800.
- 5. (a) V.G. Andrianov, A.V. Eremeev, and Y.B. Sheremet, *Khim. Geterotsikl. Soedin.*,1988, 856; (b) T. Ichikawa, T. Kato, and T. Takenishi, *J. Heterocycl. Chem.*, 1965, **2**, 253.
- 6. For reviews on Furazanes fused to 5-, 6-, and 7-membered rings see: (a) A.B. Sheremetev, J. *Heterocycl. Chem.*, 1995, **32**, 371; (b) A.B. Sheremetev, *Russian Chemical Reviews*, 1999, **68**, 137.
- 7. A.S. Kulikov, N.N. Makhova, T.I. Godovikova, S.P. Golova, and L.I. Khmel'nitskii, *Izv. Akad. Nauk, Ser. Khim.*, 1994, 679.
- (a) T.S. Novikova, T. M. Mel'nikova, O.V. Kharitonova, V.O. Kulagina, N.S. Aleksandrova, A.B. Sheremetev, T.S. Pivina, L.I. Khmel'nitskii, and S.S. Novikov, *Mendeleev Commun.*, 1994, 138; (b) A.B. Sheremetev, A.S. Kulikov, and L.I. Khmel'nitskii, *Izv. Akad. Nauk, Ser. Khim.*, 1993, 744; (c) E. Borello, A. Zecchina, and E. Guglielminotti, *Gazz. Chim. Ital.*, 1965, **95**, 1465.
- 9. For similar reaction see : A.S. Kulikov and N.N. Makhova, Izv. Akad. Nauk, Ser. Khim., 1998, 137.
- 10. Analytical and spectroscopic data are shown in the following. **1**: mp 190-192°C (H<sub>2</sub>O), (lit.,<sup>5b</sup> 190-191°C); <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$ = 4.90 (br s); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD)  $\delta$ = 155.92, 145.80, 141.19; Anal. Calcd for C<sub>3</sub>H<sub>5</sub>N<sub>5</sub>O<sub>2</sub> : C, 25.18; H, 3.52; N, 48.94. Found: C, 25.25; H, 3.48; N,

48.91; MS (electrospray): 142 (M-H<sup>+</sup>). **4m**: amorphous powder; <sup>1</sup>H NMR (300 MHz, DMSO d<sub>6</sub>)  $\delta =$ 9.00 (s, 1H), 6.35 (s, 2H), 3.50 (m, 2x2H), 3.28 (s, 3H);  $^{13}$ C NMR (75 MHz, DMSO d<sub>6</sub>)  $\delta$ = 171.61, 158.89, 155.31, 137.34, 69.94, 57.88, 42.85; MS (electrospray): 225 (M-H<sup>+</sup>), 261 (M+Cl<sup>-</sup>), 451  $(2M-H^{+})$ . 5: mp 208-210°C (decomp), (isopropanol); <sup>1</sup>H NMR (300 MHz, DMSO d<sub>6</sub>)  $\delta$ = 7.30 (br s, 2H), 6.80 (br s, 1H);  ${}^{13}$ C NMR (75 MHz, DMSO d<sub>6</sub>)  $\delta$ = 172.46, 159.23, 155.29, 138.99; HRMS (EI): Calcd 169.0236 Found: 169.0233. 9: mp 136-138°C (CH<sub>3</sub>OH); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ= 5.50 (br s, 2H), 2.51 (s, 3H), 2.30 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$ = 166.87, 155.10, 154.38, 142.69, 19.28, 13.50. **10**: mp 94-95°C (CH<sub>2</sub>Cl<sub>2</sub>), (lit., <sup>7</sup> 96°C); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ = 5.20 (s, 2H), 2.74 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$ = 192.84, 155.17, 143.49, 28.16; MS (EI) 127 (M<sup>+</sup>). **11**: mp 162°C (CH<sub>2</sub>Cl<sub>2</sub>), (lit.,<sup>8b</sup> 162-163°C); <sup>1</sup>H NMR (300 MHz, DMSO d<sub>6</sub>)  $\delta$ = 6.50 (br s, 2H), 4.87 (s, 2H); <sup>13</sup>C NMR (75 MHz, DMSO  $d_6$ )  $\delta$ = 184.72, 155.67, 141.91, 34.34; MS (EI) 207, 205 (M<sup>+</sup>). **13f**: amorphous powder; <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD)  $\delta$ = 7.20 (s, 1H), 4.80 (br s, 4H); <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD)  $\delta$ = 171.70, 156.40, 142.38, 136.42, 109.07; MS (electrospray): 182 (M-H<sup>+</sup>), 228(M+HCOO<sup>-</sup>), 262, 264 (M+Br<sup>-</sup>); MS (electrospray): 184 (M+H<sup>+</sup>), 225 (M+CH<sub>3</sub>CN+H<sup>+</sup>). **15**: mp 109°C (ethyl acetate); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  = 7.10 (d, J = 15.6 Hz, 1H), 6.80 (dd, J = 15.6 and 11.3 Hz, 1H), 5.20 (br s, 1H), 1.75 (m, 1H), 1.15 (m, 2H), 0.85 (m, 2H);  $^{13}$ C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$ = 182.11, 158.81, 156.05, 143.32, 123.09, 15.98, 10.25; MS (electrospray): 180  $(M+H^{+})$ . 22: mp 122-124°C (Hexane); <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ = 7.40-7.20 (m, 6H), 5.55 (br s, 1H), 5.20 (br s, 2H), 4.58 (d, J = 6.2 Hz, 2H), 1.95 (m, 1H), 1.15 (m, 2H), 1.05 (m, 2H); MS (electrospray): 309 (M+H<sup>+</sup>); MS (electrospray): 307 (M-H<sup>+</sup>), 343 (M+Cl<sup>-</sup>), 367 (M+CH<sub>3</sub>COO<sup>-</sup>), 651  $(2M+Cl^{-})$ . 27: amorphous powder; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$ = 7.32 (s, 1H), 6.38 (m, 1H), 6.34 (m, 1H), 5.71 (m, 1H), 5.20 (br s, 2H), 3.15 (m, 2H), 2.39 (s, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta =$ 168.65, 154.27, 150.83, 142.52, 142.43, 140.24, 110.70, 108.53, 53.20, 38.32, 22.01.